An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer's Disease.
J Alzheimers Dis Rep
; 8(1): 1111-1114, 2024.
Article
em En
| MEDLINE
| ID: mdl-39114556
ABSTRACT
We conducted a small, open-label, pilot study of daratumumab to explore target engagement, safety, and potential efficacy in patients with mild to moderate Alzheimer's disease. Daratumumab SC 1800âmg was given subcutaneously weekly for 8 weeks, then every 2 weeks for 16 weeks. Flow cytometry to measure the CD38+ proportion of CD8â+âCD4- T cells and cognitive assessments were performed at baseline, day 176, and day 246. Daratumumab significantly reduced CD38â+âCD8â+âCD4- T cells after 24 weeks and this effect persisted 11 weeks thereafter. There was no hematological toxicity or unexpected adverse events. Responder analysis showed no improvement on cognitive outcome measures.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Alzheimers Dis Rep
Ano de publicação:
2024
Tipo de documento:
Article